Medicine and Dentistry
Liver Transplantation
100%
Cohort Analysis
89%
Liver Cirrhosis
69%
Kidney Graft
62%
Quality of Life
49%
Transplantation
48%
Nonalcoholic Fatty Liver
45%
Liver Graft
41%
All Cause Mortality
32%
Machine Perfusion
31%
End Stage Liver Disease
30%
Branched Chain Amino Acid
28%
Gut Microbiome
24%
Disease
24%
Liver Disease
22%
Proton-Pump Inhibitor
21%
Metabolic Syndrome
21%
Hepatitis C
21%
Prevalence
20%
Fatty Liver
17%
Cardiovascular Disease
17%
Dysbiosis
16%
Graft Survival
16%
Clinical Trial
16%
Amyloidosis
16%
Trimethylamine
16%
Population
16%
Cholestasis
15%
Thrombosis
15%
Arm
15%
Transthyretin
15%
Antiviral Therapy
15%
Adverse Event
14%
Maturity Onset Diabetes of the Young
14%
Hepatocellular Adenoma
14%
Liver Fibrosis
14%
Non-Alcoholic Fatty Liver Disease
14%
Hepatocellular Carcinoma
14%
Iron Deficiency
13%
Biological Marker
13%
Antivirus Agent
13%
Gut
11%
Solid Organ Transplantation
10%
Diabetes
10%
Blood Stasis
10%
Diagnosis
9%
Infusion
9%
Anemia
9%
Neoplasm
9%
Homeostasis
9%
Keyphrases
Kidney Transplant Recipients
62%
Health-related Quality of Life
49%
All-cause Mortality
47%
Biobank
46%
Non-alcoholic Fatty Liver Disease (NAFLD)
42%
Solid Organ Transplant Recipients
35%
Proton Pump Inhibitors
35%
Liver Transplant Recipients
32%
Transplant Recipients
30%
Cirrhosis
29%
Transplantation
29%
End-stage Liver Disease
29%
Branched-chain Amino Acids
28%
Liver Cirrhosis
22%
Fatty Liver Index
22%
Liver Transplantation
20%
Orthotopic Liver Transplantation
20%
Pretransplant
19%
Iron Deficiency
18%
Liver
18%
Gut Microbiome
16%
Netherlands
16%
Metabolic-associated Fatty Liver Disease (MAFLD)
16%
Gut Dysbiosis
16%
Tacrolimus
16%
Metabolic Syndrome
15%
Cirrhotic Patients
15%
Daily Functioning
14%
Extracellular Vesicles
14%
Therapeutic Implications
14%
Cardiovascular Disease
11%
Type 2 Diabetes Mellitus (T2DM)
11%
Dutch
11%
Solid Organ Transplantation
10%
Nonalcoholic Steatohepatitis
10%
Mortality Risk
10%
Whole Blood
10%
Hepatic Steatosis Index
10%
Diabetes
10%
Groningen
9%
Low-density Lipoprotein
9%
Trimethylamine N-oxide
9%
Disease Groups
9%
Obesity
9%
High Risk
9%
Kidney Transplantation
8%
High-sensitivity C-reactive Protein (hs-CRP)
8%
High Prevalence
8%
Tremor
8%
C-reactive Protein
8%
Pharmacology, Toxicology and Pharmaceutical Science
Nonalcoholic Fatty Liver
71%
Cohort Study
67%
Liver Cirrhosis
45%
All Cause Mortality
38%
Fatty Liver
32%
Proton Pump Inhibitor
28%
Prevalence
20%
Disease
17%
Antivirus Agent
16%
Metabolic Syndrome X
16%
Tacrolimus
15%
C Reactive Protein
14%
Hepatitis C
14%
Liothyronine
14%
Palmitic Acid
14%
Liotrix
14%
Anticoagulant Agent
14%
Branched Chain Amino Acid
14%
Hepatitis E Virus
14%
Virus Infection
14%
Ribavirin
14%
Cardiovascular Disease
13%
Iron Deficiency
13%
Ethanol
13%
Cholestasis
12%
Liver Disease
11%
End Stage Liver Disease
11%
Omeprazole
11%
Liver Fibrosis
10%
Observational Study
10%
Clinical Trial
10%
Cardiovascular Risk
9%
Lipotoxicity
8%
Chronic Liver Disease
8%
Therapeutic Drug Monitoring
8%
Pharmacogenomics
8%
Thyrotropin
8%
Infection
8%
Lipoprotein
8%
Adverse Event
7%
Clinical Study
7%
Esomeprazole
7%
Insulin Resistance
7%
Chronic Hepatitis
7%
Hepatitis C Virus
7%
Fibrosis
7%
Chronic Inflammation
7%
Glycoprotein
7%
Disease Association
7%
Mycophenolic Acid
7%
